PhRMApedia Resources

PhRMA Fact Sheets

RxE HCV in Virginia

Chronic hepatitis C (HCV) is a devastating viral disease that kills more Americans each year than HIV/AIDS. It is the leading cause of cirrhosis and liver cancer and is the most common reason for a liver transplant in the United States. Until recently, the only available treatment for HCV was a 48 week course of combination pegylated interferon/ribavirin which often came with debilitating, flu-like side effects and only cured about half of patients.

Read More
RxE HCV in New Hampshire

Chronic hepatitis C (HCV) is a devastating viral disease that kills more Americans each year than HIV/AIDS. It is the leading cause of cirrhosis and liver cancer and is the most common reason for a liver transplant in the United States. Until recently, the only available treatment for HCV was a 48 week course of combination pegylated interferon/ribavirin which often came with debilitating, flu-like side effects and only cured about half of patients.

Read More
RxE HCV in Florida

Chronic hepatitis C (HCV) is a devastating viral disease that kills more Americans each year than HIV/AIDS. It is the leading cause of cirrhosis and liver cancer and is the most common reason for a liver transplant in the United States. Until recently, the only available treatment for HCV was a 48 week course of combination pegylated interferon/ribavirin which often came with debilitating, flu-like side effects and only cured about half of patients.

Read More
RxE HCV in New Mexico

Chronic hepatitis C (HCV) is a devastating viral disease that kills more Americans each year than HIV/AIDS. It is the leading cause of cirrhosis and liver cancer and is the most common reason for a liver transplant in the United States. Until recently, the only available treatment for HCV was a 48 week course of combination pegylated interferon/ribavirin which often came with debilitating, flu-like side effects and only cured about half of patients.

Read More
RxE HCV in Illinois

Chronic hepatitis C (HCV) is a devastating viral disease that kills more Americans each year than HIV/AIDS. It is the leading cause of cirrhosis and liver cancer and is the most common reason for a liver transplant in the United States. Until recently, the only available treatment for HCV was a 48 week course of combination pegylated interferon/ribavirin which often came with debilitating, flu-like side effects and only cured about half of patients.

Read More
RxE HCV in New York

Chronic hepatitis C (HCV) is a devastating viral disease that kills more Americans each year than HIV/AIDS. It is the leading cause of cirrhosis and liver cancer and is the most common reason for a liver transplant in the United States. Until recently, the only available treatment for HCV was a 48 week course of combination pegylated interferon/ribavirin which often came with debilitating, flu-like side effects and only cured about half of patients.

Read More
RxE HCV in Indiana

Chronic hepatitis C (HCV) is a devastating viral disease that kills more Americans each year than HIV/AIDS. It is the leading cause of cirrhosis and liver cancer and is the most common reason for a liver transplant in the United States. Until recently, the only available treatment for HCV was a 48 week course of combination pegylated interferon/ribavirin which often came with debilitating, flu-like side effects and only cured about half of patients.

Read More
RxE HCV in Ohio

Chronic hepatitis C (HCV) is a devastating viral disease that kills more Americans each year than HIV/AIDS. It is the leading cause of cirrhosis and liver cancer and is the most common reason for a liver transplant in the United States. Until recently, the only available treatment for HCV was a 48 week course of combination pegylated interferon/ribavirin which often came with debilitating, flu-like side effects and only cured about half of patients.

Read More
RxE HCV in Louisiana

Chronic hepatitis C (HCV) is a devastating viral disease that kills more Americans each year than HIV/AIDS. It is the leading cause of cirrhosis and liver cancer and is the most common reason for a liver transplant in the United States. Until recently, the only available treatment for HCV was a 48 week course of combination pegylated interferon/ribavirin which often came with debilitating, flu-like side effects and only cured about half of patients.

Read More
RxE HCV in Pennsylvania

Chronic hepatitis C (HCV) is a devastating viral disease that kills more Americans each year than HIV/AIDS. It is the leading cause of cirrhosis and liver cancer and is the most common reason for a liver transplant in the United States. Until recently, the only available treatment for HCV was a 48 week course of combination pegylated interferon/ribavirin which often came with debilitating, flu-like side effects and only cured about half of patients. The past couple years have seen a transformation in treatment with the introduction of a new generation of HCV medicines which provide cure rates upwards of 90% with minimal side effects and in as little as 8 weeks.

Read More
RxE HCV in California

Chronic hepatitis C (HCV) is a devastating viral disease that kills more Americans each year than HIV/AIDS. It is the leading cause of cirrhosis and liver cancer and is the most common reason for a liver transplant in the United States. Until recently, the usual treatment for HCV was a 48-week course of combination pegylated interferon/ribavirin that often came with debilitating, flu-like side effects and only cured about half of patients.

Read More
Access to Multiple Sclerosis Medicines in Exchange Plans (2015)

Medicines are a critical component of long-term management of multiple sclerosis (MS) and prevention of the disease’s progression. MS is an autoimmune inflammatory disease of the central nervous system that is a leading cause of disability in young adults.

Read More
Access to Rheumatoid Arthritis Medicines in Exchange Plans (2015)

Prescription medicines are an essential component of treatment for rheumatoid arthritis (RA). RA is an autoimmune disease that causes chronic joint inflammation and painful swelling that may result in long-term damage and disability.

Read More
Access to Diabetes Medicines in Exchange Plans (2015)

The number of patients who are newly diagnosed with diabetes each year has tripled in the past twenty years, and type 2 diabetes accounts for 95% of diagnosed diabetes in adults. As many previously uninsured people enroll in exchange coverage and access primary care, diagnoses of diabetes may increase further. Medicines are a key component of managing diabetes. Most patients take oral medicines to stabilize blood sugar levels, but over time, many patients also add insulin to their treatment regimens.

Read More
Access to Asthma Medicines in Exchange Plans (2015)

Prescription medicines are a crucial component of treatment for asthma. In the United States, more than 25 million people are known to have asthma, including about 7 million children. Goals of asthma treatment include reduced impairment from symptoms; minimized risk of asthma attacks and other adverse outcomes, such as hospitalizations and loss of lung function; and minimized side effects of asthma medicines. Treatment with medicines is the key to successfully managing asthma for most patients. One recent study found that children with low adherence to certain asthma medicines experience a higher risk of emergency department visits and hospital admissions compared to children with better adherence.

Read More

Pages